ImmunoCellular Therapeutics Ltd (NYSEMKT:IMUC) announced it has entered into a sponsored research agreement with Eduardo Davila, PhD, Associate Professor of Microbiology and Immunology at the University of Maryland School of Medicine, and the University of Maryland, Baltimore.  The agreement includes three projects, which together have the potential to improve the efficacy of dendritic cell, T-cell, and combination immunotherapies for cancer and lead to enhancements to both of ImmunoCellular’sdendritic cell and Stem-to-T-cell platforms.

  • The first of three projects evaluates certain immune modulators that could enhance T-cell killing of tumor cells. These small molecule modulators have been shown preclinically to be capable of increasing tumor antigen expression while simultaneously decreasing expression of ligands, such as PD-L1 and PDL2, which decrease T-cell activity. This technology applies directly to both ImmunoCellular platforms.
  • The second project explores the combination of engineered killer T-cells and dendritic cell immunotherapies on tumor killing. These T-cells embody a novel engineering technology that potentially amplifies their cytotoxic, proliferative, and cytokine-producing properties toward tumor antigens. Combining these engineered T-cells with ImmunoCellular’s dendritic cell immunotherapies could lead to enhanced tumor cell killing.
  • The third project tests novel peptide configurations for use with dendritic cell immunotherapies to potentially induce enhanced T-cell responses.

Dr. Davila is the Program Leader for the Tumor Immunology and Immunotherapy Program within the University of Maryland Marlene and Stewart Greenebaum Cancer Center Program. As such, he collaborates with both basic and clinical research investigators to understand the immune regulation of malignant disease and translate this knowledge into the development of novel diagnostic, preventative and treatment regimens.

“ImmunoCellular’s research and early development strategy is to complement and enhance our dendritic cell and Stem-to-T-cell technology platforms and create potent cell-based cancer immunotherapeutic clinical candidates and combinations,” said Steven Swanson, PhD,ImmunoCellular Senior Vice President, Research. “The research projects we are undertaking with Dr. Davila align well with this strategy and have the potential to lead to platform technology enhancements and new clinical programs.”

“With this agreement and with other related research underway, we are systematically delivering on our goal to build a leading cancer immunotherapy company.  We are pleased with the enhanced position we are establishing in the dendritic cell and T-cell cancer immunotherapy space,” said Andrew Gengos, ImmunoCellular Chief Executive Officer. (Original Source)

Shares of ImmunoCellular closed yesterday at $0.24. IMUC has a 1-year high of $0.73 and a 1-year low of $0.21. The stock’s 50-day moving average is $0.33 and its 200-day moving average is $0.41.

On the ratings front, Roth Capital analyst Joseph Pantginis reiterated a Buy rating on IMUC, with a price target of $3, in a report issued on November 12. The current price target implies an upside of 1150.0% from current levels. According to, Pantginis has a total average return of -12.2%, a 32.4% success rate, and is ranked #3591 out of 3607 analysts.

ImmunoCellular Therapeutics Ltd is a clinical-stage biotechnology company that develops immune-based therapies for the treatment of cancers, such as brain, ovarian and other solid tumors.